The IP6K1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human SK-HEP-1 hepatocellular carcinoma cell line, enabling functional ablation of the IP6K1 gene. By generating a mixed population of gene-edited cells without clonal isolation, this product preserves the intrinsic heterogeneity of liver cancer cells, providing a physiologically relevant model for loss-of-function studies. The polyclonal format circumvents the potential artifacts of single-cell clones and is especially useful for investigating population-level phenotypic responses in cancer biology.
The parental SK-HEP-1 cell line was originally established from the ascites of a male patient with liver adenocarcinoma and is widely employed as a model for hepatocellular carcinoma. These adherent epithelial cells maintain characteristic features of hepatic cancer, including dysregulated growth factor signaling and metabolic alterations. Their well-characterized genotype and phenotypic stability make them an ideal host background for examining the role of IP6K1 in liver tumorigenesis and progression.
IP6K1 encodes inositol hexakisphosphate kinase 1, a central enzyme in inositol phosphate metabolism that catalyzes the conversion of InsP6 to the inositol pyrophosphates IP7 and IP8. These high-energy signaling molecules function as intracellular metabolic messengers, with IP7 directly activating Akt by facilitating its membrane recruitment and phosphorylation via PDK1. IP6K1 activity is modulated by upstream regulators including InsP6, Akt, AMPK, and growth factors, and the kinase interacts with HSP90 and ARF6. Through IP7 production, IP6K1 governs key processes such as insulin-responsive Akt/GSK3?? signaling, DNA damage repair, and apoptosis. Consequently, IP6K1 serves as a critical node connecting phosphate sensing and energy metabolism to cell survival and proliferation.
In the SK-HEP-1 hepatocellular carcinoma context, disruption of IP6K1 expression ablates IP7 synthesis, leading to suppressed Akt phosphorylation, diminished proliferation, and altered apoptotic thresholds and DNA repair capacity. As IP6K1 is often dysregulated in liver cancer and linked to metabolic rewiring, this polyclonal knockout model provides a powerful system to dissect inositol pyrophosphate-dependent oncogenic pathways. It enables investigation of tumor cell dependence on IP6K1-mediated signaling and the identification of downstream vulnerabilities for therapeutic intervention.
This product supports a wide array of applications, including Western blot analysis of IP6K1 and IP7 levels, Akt phospho-assays, Annexin V-based apoptosis detection, MTT cell viability assays, and transwell migration/invasion studies. Transcriptional profiling via RT-qPCR can assess changes in downstream targets such as GSK3??. The polyclonal knockout population is also suitable for drug target validation, metabolic flux experiments, and rescue assays. For further information, please contact Ascent Research.
